PPARA

Peroxisome proliferator-activated receptor alpha · Q07869 · PPARA on Sugi Atlas →

573,402 patent compounds predicted against PPARA, 298,932 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Tesaglitazar (SCHEMBL16594)	1.00	19/20
SCHEMBL3922	0.61	16/20
Bezafibrate (SCHEMBL16299)	1.00	13/20
Fenofibric Acid (SCHEMBL16377)	1.00	12/20
SCHEMBL31933	0.55	11/20
SCHEMBL31960	0.63	10/20
SCHEMBL2053	0.50	10/20
Gemfibrozil (SCHEMBL4813)	1.00	9/20
SCHEMBL31889	0.51	9/20
Clinofibrate (SCHEMBL31290)	0.47	9/20
Ciprofibrate (SCHEMBL26870)	1.00	8/20
SCHEMBL30675	0.52	8/20
SCHEMBL31881	0.50	8/20
SCHEMBL18216	0.45	8/20
SCHEMBL18217	0.45	8/20
Stearic Acid (SCHEMBL659)	1.00	7/20
Clofibrate (SCHEMBL2356)	1.00	7/20
Decanoic Acid (SCHEMBL2682)	1.00	7/20
Octanoic Acid (SCHEMBL3933)	1.00	7/20
Fenofibrate (SCHEMBL4670)	1.00	7/20

Clinical trials — most relevant to PPARA by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effects of Peroxisome Proliferators Activated Receptor-Gamma (PPAR-γ) Agonists on Certain Biochemical and Inflammatory Markers in Metabolic Syndrome	PHASE4	COMPLETED
Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone	PHASE4	COMPLETED
Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients	PHASE4	COMPLETED
Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.	PHASE4	COMPLETED
Pioglitazone Therapy in Obese Children With Insulin Resistance: A Randomized, Controlled Pilot Study	PHASE4	WITHDRAWN
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)	PHASE4	COMPLETED
Dapagliflozin Plus Pioglitazone in T1DM	PHASE4	RECRUITING
Evaluate the Efficacy of Fenofibrate on Microalbuminuria	PHASE4	UNKNOWN
Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes	PHASE3	COMPLETED
Fenofibrate in Ulcerative Colitis	PHASE2/PHASE3	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)	PHASE2	COMPLETED
A Study in People With Mild Hypertension	PHASE2	COMPLETED
Bioenergetic Effect of Pioglitazone in CLD-PH	PHASE2	RECRUITING
Pioglitazone Therapy Targeting Fatigue in Breast Cancer	PHASE2	RECRUITING
Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects	PHASE2	COMPLETED
Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients	PHASE2	COMPLETED
Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular Disease	PHASE2	COMPLETED
Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes	PHASE2	COMPLETED
Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery	PHASE2	COMPLETED
The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients	nan	COMPLETED
Effect of a PPAR-Alpha Agonist on the Age Related Changes in Myocardial Metabolism and Mechanical Function	nan	UNKNOWN
Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy	nan	COMPLETED
Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients	nan	COMPLETED
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes	nan	COMPLETED
The Impact of Rosiglitazone on Regression of Atherosclerosis	nan	SUSPENDED
Study of the Function of Cells Involved in Inflammation in the Lungs of Those With Acute Lung Injury and Sepsis	nan	COMPLETED
Role of FGF21 in Breast Cancer	nan	NOT_YET_RECRUITING
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.	nan	COMPLETED
In and ex Vivo Mitochondrial Function of the Heart	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PPARA binder may also engage these)

Protein	Name	Similarity
Q8HYL6	—	1.000	Q8HYL6 →
P23204	—	1.000	P23204 →
P37230	—	1.000	P37230 →
O35507	—	1.000	O35507 →
Q95N78	—	1.000	Q95N78 →
P37232	—	1.000	P37232 →
Q0ZAQ8	—	1.000	Q0ZAQ8 →
P57797	—	1.000	P57797 →
O01930	—	1.000	O01930 →
Q9XTJ4	—	0.999	Q9XTJ4 →
O18971	—	0.999	O18971 →
O62807	—	0.999	O62807 →
O45436	—	0.999	O45436 →
Q9N4Q7	—	0.998	Q9N4Q7 →
O17611	—	0.998	O17611 →
O18924	—	0.998	O18924 →
Q8ITW8	—	0.998	Q8ITW8 →
Q21878	—	0.998	Q21878 →
P37234	—	0.998	P37234 →
P31396	—	0.998	P31396 →
O17898	—	0.998	O17898 →
P28700	—	0.998	P28700 →
P35396	—	0.998	P35396 →
O19052	—	0.998	O19052 →
P37238	—	0.998	P37238 →
P79926	—	0.998	P79926 →
P49882	—	0.997	P49882 →
Q9XYB7	—	0.997	Q9XYB7 →
P51129	—	0.997	P51129 →
PPARD	Peroxisome proliferator-activated receptor delta	0.997	landscape →